Table 1.
Baseline values and percent change in serum inflammatory markers
| Baseline values (mean± sem) | 3 months
|
6 months
|
||||
|---|---|---|---|---|---|---|
| Etanercept | Placebo | Treatment effect vs. placebo (% change) | P value | Treatment effect vs. placebo (% change) | P value | |
| TNF-α (pg/ml) | 3.4 ± 1.8 | 0.9 ± 0.5 | +55 ± 25 | 0.08 | +51 ± 17 | 0.03 |
| TNFR2 (pg/ml) | 2366 ± 111 | 2499 ± 125 | +103 ± 6 | <0.0001 | +98 ± 4 | <0.0001 |
| IL-6 (pg/ml) | 10.5 ± 1.6a | 7.2 ± 0.7 | −4 ± 22 | 0.85 | −1 ± 14 | 0.92 |
| Total adiponectin (ng/ml) | 3306 ± 265 | 4376 ± 601 | −12 ± 5 | 0.01 | −12 ± 4 | 0.004 |
| HMW adiponectin (ng/ml) | 761 ± 145 | 1418 ± 257 | +3 ± 17 | 0.85 | +13 ± 11 | 0.26 |
| HMW/total adiponectin | 0.31 ± 0.13 | 0.38 ± 0.10 | +13 ± 14 | 0.35 | +22 ± 9 | 0.02 |
| sICAM-1 (ng/ml) | 231 ± 26 | 211 ± 13 | −12 ± 2 | <0.0001 | −11 ± 2 | <0.0001 |
| VCAM-1 (μm) | 494 ± 28 | 562 ± 48 | −1 ± 6 | 0.84 | −2.7 ± 4 | 0.51 |
| Resistin (ng/ml) | 8.8 ± 1.0 | 7.4 ± 0.5 | −21 ± 18 | 0.24 | −20 ± 11 | 0.08 |
a
Baseline IL-6 significantly different between etanercept and placebo groups (P = 0.03). No other baseline variables were significantly different between etanercept and placebo groups.